CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone

A case report

Hideaki Nakajima, Masahiro Kizaki, Yohko Kawai, Akaru Ishida, Michihide Tokuhira, Kiyoaki Watanabe, Yasuo Ikeda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A 45-year-old woman with acute lymphoblastic leukemia (ALL) who failed to achieve complete remission (CR) after one course of induction chemotherapy with vincristine, daunorubicin, prednisolone and l-asparaginase was successfully treated with a high dose of cytosine arabinoside (Ara-C) and mitoxantrone. The leukemic blasts were CD7, 19, 33, and 38 antigens positive, and had a rearrangement in the T-cell receptor δ chain gene. The karyotype was normal. Primary induction failure and positivity for myeloid antigens are both reported to be poor prognostic factors for ALL. Nevertheless, this patient was successfully treated with the high dose Ara-C and mitoxantrone, and she remains in CR for over 20 months. Combination chemotherapy with high dose Ara-C and mitoxantron may be of benefit for refractory ALL with both CD7 and myeloid antigens.

Original languageEnglish
Pages (from-to)114-117
Number of pages4
JournalKeio Journal of Medicine
Volume45
Issue number2
Publication statusPublished - 1996 Jun

Fingerprint

Mitoxantrone
Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CD7 Antigens
T-Cell Receptor Genes
Antigens
Asparaginase
Induction Chemotherapy
Daunorubicin
Vincristine
Prednisolone
Combination Drug Therapy
Karyotype

Keywords

  • acute lymphoblastic leukemia
  • CD7
  • cytosine arabinoside
  • mitoxantrone
  • treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nakajima, H., Kizaki, M., Kawai, Y., Ishida, A., Tokuhira, M., Watanabe, K., & Ikeda, Y. (1996). CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: A case report. Keio Journal of Medicine, 45(2), 114-117.

CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone : A case report. / Nakajima, Hideaki; Kizaki, Masahiro; Kawai, Yohko; Ishida, Akaru; Tokuhira, Michihide; Watanabe, Kiyoaki; Ikeda, Yasuo.

In: Keio Journal of Medicine, Vol. 45, No. 2, 06.1996, p. 114-117.

Research output: Contribution to journalArticle

Nakajima, H, Kizaki, M, Kawai, Y, Ishida, A, Tokuhira, M, Watanabe, K & Ikeda, Y 1996, 'CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: A case report', Keio Journal of Medicine, vol. 45, no. 2, pp. 114-117.
Nakajima, Hideaki ; Kizaki, Masahiro ; Kawai, Yohko ; Ishida, Akaru ; Tokuhira, Michihide ; Watanabe, Kiyoaki ; Ikeda, Yasuo. / CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone : A case report. In: Keio Journal of Medicine. 1996 ; Vol. 45, No. 2. pp. 114-117.
@article{f825c17001fc42e490761afb67f077bb,
title = "CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone: A case report",
abstract = "A 45-year-old woman with acute lymphoblastic leukemia (ALL) who failed to achieve complete remission (CR) after one course of induction chemotherapy with vincristine, daunorubicin, prednisolone and l-asparaginase was successfully treated with a high dose of cytosine arabinoside (Ara-C) and mitoxantrone. The leukemic blasts were CD7, 19, 33, and 38 antigens positive, and had a rearrangement in the T-cell receptor δ chain gene. The karyotype was normal. Primary induction failure and positivity for myeloid antigens are both reported to be poor prognostic factors for ALL. Nevertheless, this patient was successfully treated with the high dose Ara-C and mitoxantrone, and she remains in CR for over 20 months. Combination chemotherapy with high dose Ara-C and mitoxantron may be of benefit for refractory ALL with both CD7 and myeloid antigens.",
keywords = "acute lymphoblastic leukemia, CD7, cytosine arabinoside, mitoxantrone, treatment",
author = "Hideaki Nakajima and Masahiro Kizaki and Yohko Kawai and Akaru Ishida and Michihide Tokuhira and Kiyoaki Watanabe and Yasuo Ikeda",
year = "1996",
month = "6",
language = "English",
volume = "45",
pages = "114--117",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "2",

}

TY - JOUR

T1 - CD7 positive acute lymphoblastic leukemia successfully treated with high dose cytosine arabinoside and mitoxantrone

T2 - A case report

AU - Nakajima, Hideaki

AU - Kizaki, Masahiro

AU - Kawai, Yohko

AU - Ishida, Akaru

AU - Tokuhira, Michihide

AU - Watanabe, Kiyoaki

AU - Ikeda, Yasuo

PY - 1996/6

Y1 - 1996/6

N2 - A 45-year-old woman with acute lymphoblastic leukemia (ALL) who failed to achieve complete remission (CR) after one course of induction chemotherapy with vincristine, daunorubicin, prednisolone and l-asparaginase was successfully treated with a high dose of cytosine arabinoside (Ara-C) and mitoxantrone. The leukemic blasts were CD7, 19, 33, and 38 antigens positive, and had a rearrangement in the T-cell receptor δ chain gene. The karyotype was normal. Primary induction failure and positivity for myeloid antigens are both reported to be poor prognostic factors for ALL. Nevertheless, this patient was successfully treated with the high dose Ara-C and mitoxantrone, and she remains in CR for over 20 months. Combination chemotherapy with high dose Ara-C and mitoxantron may be of benefit for refractory ALL with both CD7 and myeloid antigens.

AB - A 45-year-old woman with acute lymphoblastic leukemia (ALL) who failed to achieve complete remission (CR) after one course of induction chemotherapy with vincristine, daunorubicin, prednisolone and l-asparaginase was successfully treated with a high dose of cytosine arabinoside (Ara-C) and mitoxantrone. The leukemic blasts were CD7, 19, 33, and 38 antigens positive, and had a rearrangement in the T-cell receptor δ chain gene. The karyotype was normal. Primary induction failure and positivity for myeloid antigens are both reported to be poor prognostic factors for ALL. Nevertheless, this patient was successfully treated with the high dose Ara-C and mitoxantrone, and she remains in CR for over 20 months. Combination chemotherapy with high dose Ara-C and mitoxantron may be of benefit for refractory ALL with both CD7 and myeloid antigens.

KW - acute lymphoblastic leukemia

KW - CD7

KW - cytosine arabinoside

KW - mitoxantrone

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=0029900376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029900376&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 114

EP - 117

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 2

ER -